KEYMED BIOSCIENCES -0001 (64Z) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.49x
KEYMED BIOSCIENCES -0001 (64Z) has a Cash Flow-to-Debt Ratio of -0.49x as of December 2025, meaning its operating cash flow of €-712.41 Million could theoretically repay 0% of its total liabilities (€1.44 Billion) in one year. See 64Z financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.49x
Operating CF / Total Liabilities
Operating Cash Flow
€-712.41 Million
EUR
Total Liabilities
€1.44 Billion
EUR
Data as of
Dec 2025
Most recent filing
KEYMED BIOSCIENCES -0001 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for KEYMED BIOSCIENCES -0001 across 5 annual periods. For the full cash flow conversion analysis, see KEYMED BIOSCIENCES -0001 cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for KEYMED BIOSCIENCES -0001 (2021–2025)
Year-by-year debt coverage analysis for KEYMED BIOSCIENCES -0001.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.49x | €-712.41 Million | €1.44 Billion | ▲ +19.2% |
| 2024 | -0.61x | €-789.63 Million | €1.29 Billion | ▼ -80.5% |
| 2023 | -0.34x | €-303.62 Million | €896.11 Million | ▲ +50.0% |
| 2022 | -0.68x | €-401.93 Million | €593.10 Million | ▲ +8.7% |
| 2021 | -0.74x | €-214.64 Million | €289.07 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.